Medicxi launches €500M biotech fund

Team S · 2025-11-20T12:20:31.000Z

Medicxi, a life sciences venture capital firm based in London and Geneva, has raised €500 million (approximately $581.6 million) for its sixth fund The fund will support innovative biotech companies with product visions to transform patient care, targeting asset-focused biotechs across all stages of development. Since its last fundraising, Medicxi created 16 new companies and realized more than $1 billion in returns from its portfolio, including notable exits such as Sanofi’s $1.15 billion acquisition of Vicebio and Eli Lilly’s purchase of Versanis Bio. Over the past decade, Medicxi has closed six funds, managing more than €2 billion in total commitments. Recent investments include backing Curevo Vaccine’s $110 million Series B to challenge GSK’s shingles vaccine, Shingrix. Medicxi’s portfolio also features prominent vaccine ventures like Vaxcyte and Vicebio. Co-founder and partner Giovanni Mariggi emphasized the firm’s capital-efficient and rapidly scaling investment strategy.

Member Login Get Access

Medicxi launches €500M biotech fund | Newnex